Cephalexin Oral Suspension 250mg (Teva) – Potency Inconsistency (2020)
Class II: A situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Class II recall indicates potential for temporary health effects.
This AI-generated summary is provided for general informational purposes only and is derived from publicly available recall notices. It supplements but does not replace official agency classifications or safety instructions.
Check Your Product
According to the U.S. Food and Drug Administration (FDA)
Product
Cephalexin for Oral Suspension, USP 250 mg per 5 mL, For Reconstitution, For Oral Use Only, Rx Only, a) 100 mL bottle when mixed, NDC 0093-4177-73, b) 200 mL bottle when mixed, NDC 0093-4177-74, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454.
Brand
Teva Pharmaceuticals USA
Lot Codes / Batch Numbers
Lot #s: a) 30309862A, 30309863A, Exp. 08/2020, 30309928A, 30309929A, Exp. 09/2020, 30310029A, 30310030A, 30310033A, 30310034A, Exp. 10/2020, 30310035A, 30310079A, 30310080A, 30310081A, Exp. 11/2020, 30310134A, 30310135A, Exp. 01/2021, 30310182A, 30310183A, 30310210A, Exp. 02/2021, 30310211A, 30310246A, Exp. 03/2021, 30310282A, Exp. 04/2021, 30310290A, Exp. 05/2021, 30310394A, 30310395A, Exp.07/2021, 30310457A, Exp. 09/2021, 30310506A, 30310507A, Exp. 10/2021, 30310555A, 30310605A, Exp. 11/2021. b) 30309864A, 30309865A, Exp. 08/2020, 30309930A, 30309931A, Exp. 09/2020, 30309991A, 30309992A, 30310028A, Exp.10/2020, 30310036A, 30310037A, 30310038A, Exp. 11/2020, 30310082A, 30310083A, Exp. 12/2020, 30310136A, 30310137A, Exp. 01/2021, 30310184A, 30310185A, Exp. 02/2021, 30310212A, Exp. 03/2021, 30310303A, Exp. 04/2021, 30310327A, Exp. 06/2021, 30310396A, 30310407A, Exp. 08/2021, 30310445A, Exp. 09/2021, 30310556A, Exp. 10/2021.
Products Sold
Lot #s: a) 30309862A, 30309863A, Exp. 08/2020; 30309928A, 30309929A, Exp. 09/2020; 30310029A, 30310030A, 30310033A, 30310034A, Exp. 10/2020; 30310035A, 30310079A, 30310080A, 30310081A, Exp. 11/2020; 30310134A, 30310135A, Exp. 01/2021; 30310182A, 30310183A, 30310210A, Exp. 02/2021; 30310211A, 30310246A, Exp. 03/2021; 30310282A, Exp. 04/2021; 30310290A, Exp. 05/2021; 30310394A, 30310395A, Exp.07/2021; 30310457A, Exp. 09/2021; 30310506A, 30310507A, Exp. 10/2021; 30310555A, 30310605A, Exp. 11/2021. b) 30309864A, 30309865A, Exp. 08/2020; 30309930A, 30309931A, Exp. 09/2020; 30309991A, 30309992A, 30310028A, Exp.10/2020; 30310036A, 30310037A, 30310038A, Exp. 11/2020; 30310082A, 30310083A, Exp. 12/2020; 30310136A, 30310137A, Exp. 01/2021; 30310184A, 30310185A, Exp. 02/2021; 30310212A, Exp. 03/2021; 30310303A, Exp. 04/2021; 30310327A, Exp. 06/2021; 30310396A, 30310407A, Exp. 08/2021; 30310445A, Exp. 09/2021; 30310556A, Exp. 10/2021.
Teva Pharmaceuticals USA is recalling Cephalexin for Oral Suspension, USP 250 mg per 5 mL, For Reconstitution, For Oral Use Only, Rx Only, due to CGMP deviations; there is a possibility that some bottles in these lots may have the active ingredient above and/or below specification limits.. This is a Class I recall, indicating a high risk of serious health consequences. Based on FDA drug enforcement report.
Summary derived from FDA notice
Reason for Recall
As stated by FDA
CGMP deviations; there is a possibility that some bottles in these lots may have the active ingredient above and/or below specification limits.
Recommended Action
Per FDA guidance
Consumers should stop using the product and contact the recalling firm, their healthcare provider, or return it to the place of purchase.
Verify this information on the official source
For complete details and official instructions, check the U.S. Food and Drug Administration (FDA) directly.
View official FDA recall noticePage updated: Jan 7, 2026